/PRNewswire/ Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and.
Bausch + Lomb Completes Enrollment Of First Phase 3 Study For NOV03
Phase 2 Study Published in Cornea: The Journal of Cornea and External Disease ; Study Met Primary Endpoint in Patients with Highly Symptomatic Evaporative Dry Eye Disease Associated with Meibomian Gland Dysfunction Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced … Phase 2 Study Published in Cornea: The Journal of Cornea and External Disease ; Study Met Primary Endpoint in Patients with Highly Symptomatic Evaporative Dry Eye Disease Associated with Meibomian Gland Dysfunction
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSETSX: BHC) (“Bausch Health” or the “Company”), and Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced the first of two Phas